497 related articles for article (PubMed ID: 15592431)
21. Involvement of calpain and p25 of CDK5 pathway in ginsenoside Rb1's attenuation of beta-amyloid peptide25-35-induced tau hyperphosphorylation in cortical neurons.
Chen X; Huang T; Zhang J; Song J; Chen L; Zhu Y
Brain Res; 2008 Mar; 1200():99-106. PubMed ID: 18289510
[TBL] [Abstract][Full Text] [Related]
22. Tau phosphorylation by cdk5 and Fyn in response to amyloid peptide Abeta (25-35): involvement of lipid rafts.
Hernandez P; Lee G; Sjoberg M; Maccioni RB
J Alzheimers Dis; 2009; 16(1):149-56. PubMed ID: 19158430
[TBL] [Abstract][Full Text] [Related]
23. p35/Cyclin-dependent kinase 5 is required for protection against beta-amyloid-induced cell death but not tau phosphorylation by ceramide.
Seyb KI; Ansar S; Li G; Bean J; Michaelis ML; Dobrowsky RT
J Mol Neurosci; 2007; 31(1):23-35. PubMed ID: 17416967
[TBL] [Abstract][Full Text] [Related]
24. Cyclin-dependent kinase 5--a neuronal killer?
Guo Q
Sci Aging Knowledge Environ; 2003 Dec; 2003(50):pe36. PubMed ID: 14681576
[TBL] [Abstract][Full Text] [Related]
25. The interaction of Munc 18 (p67) with the p10 domain of p35 protects in vivo Cdk5/p35 activity from inhibition by TFP5, a peptide derived from p35.
Amin ND; Zheng Y; Bk B; Shukla V; Skuntz S; Grant P; Steiner J; Bhaskar M; Pant HC
Mol Biol Cell; 2016 Nov; 27(21):3221-3232. PubMed ID: 27630261
[TBL] [Abstract][Full Text] [Related]
26. Tau neurofibrillary pathology and microtubule stability.
Michaelis ML; Dobrowsky RT; Li G
J Mol Neurosci; 2002 Dec; 19(3):289-93. PubMed ID: 12540054
[TBL] [Abstract][Full Text] [Related]
27. The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator.
Hisanaga S; Saito T
Neurosignals; 2003; 12(4-5):221-9. PubMed ID: 14673209
[TBL] [Abstract][Full Text] [Related]
28. Profiling of p5, a 24 Amino Acid Inhibitory Peptide Derived from the CDK5 Activator, p35 CDKR1 Against 70 Protein Kinases.
Binukumar BK; Pelech SL; Sutter C; Shukla V; Amin ND; Grant P; Bhaskar M; Skuntz S; Steiner J; Pant HC
J Alzheimers Dis; 2016 Sep; 54(2):525-33. PubMed ID: 27567857
[TBL] [Abstract][Full Text] [Related]
29. Involvement of cyclin dependent kinase5 activator p25 on tau phosphorylation in mouse brain.
Takashima A; Murayama M; Yasutake K; Takahashi H; Yokoyama M; Ishiguro K
Neurosci Lett; 2001 Jun; 306(1-2):37-40. PubMed ID: 11403952
[TBL] [Abstract][Full Text] [Related]
30. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
Leclerc S; Garnier M; Hoessel R; Marko D; Bibb JA; Snyder GL; Greengard P; Biernat J; Wu YZ; Mandelkow EM; Eisenbrand G; Meijer L
J Biol Chem; 2001 Jan; 276(1):251-60. PubMed ID: 11013232
[TBL] [Abstract][Full Text] [Related]
31. Deregulated Cdk5 triggers aberrant activation of cell cycle kinases and phosphatases inducing neuronal death.
Chang KH; Vincent F; Shah K
J Cell Sci; 2012 Nov; 125(Pt 21):5124-37. PubMed ID: 22899714
[TBL] [Abstract][Full Text] [Related]
32. The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology.
Maccioni RB; Otth C; Concha II; Muñoz JP
Eur J Biochem; 2001 Mar; 268(6):1518-27. PubMed ID: 11248668
[TBL] [Abstract][Full Text] [Related]
33. Neurodegeneration in an Abeta-induced model of Alzheimer's disease: the role of Cdk5.
Lopes JP; Oliveira CR; Agostinho P
Aging Cell; 2010 Feb; 9(1):64-77. PubMed ID: 19895631
[TBL] [Abstract][Full Text] [Related]
34. Specific inhibition of p25/Cdk5 activity by the Cdk5 inhibitory peptide reduces neurodegeneration in vivo.
Sundaram JR; Poore CP; Sulaimee NH; Pareek T; Asad AB; Rajkumar R; Cheong WF; Wenk MR; Dawe GS; Chuang KH; Pant HC; Kesavapany S
J Neurosci; 2013 Jan; 33(1):334-43. PubMed ID: 23283346
[TBL] [Abstract][Full Text] [Related]
35. Changes in the prefrontal cortex after the hippocampus was injected with Aβ
Wang Y; Sheng H; Zhao J; Guo L; Liu J; Xu J; Liu Q; Huang J; Jiang R; Gan S; Qiu G; Lu W; Xu S; Zhu S
Neurosci Lett; 2021 Jan; 741():135453. PubMed ID: 33186609
[TBL] [Abstract][Full Text] [Related]
36. The protective effects of tanshinone IIA on neurotoxicity induced by β-amyloid protein through calpain and the p35/Cdk5 pathway in primary cortical neurons.
Shi LL; Yang WN; Chen XL; Zhang JS; Yang PB; Hu XD; Han H; Qian YH; Liu Y
Neurochem Int; 2012 Jul; 61(2):227-35. PubMed ID: 22561406
[TBL] [Abstract][Full Text] [Related]
37. Fuzhisan, a Chinese herbal medicine, inhibits beta-amyloid-induced neurotoxicity and tau phosphorylation through calpain/Cdk5 pathway in cultured cortical neurons.
Zhang Z; Zhao R; Tang Y; Wen S; Wang D; Qi J
Neurochem Res; 2011 May; 36(5):801-11. PubMed ID: 21243427
[TBL] [Abstract][Full Text] [Related]
38. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5.
Ahlijanian MK; Barrezueta NX; Williams RD; Jakowski A; Kowsz KP; McCarthy S; Coskran T; Carlo A; Seymour PA; Burkhardt JE; Nelson RB; McNeish JD
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2910-5. PubMed ID: 10706614
[TBL] [Abstract][Full Text] [Related]
39. The inhibition of Cdk5 activity after hypoxia/ischemia injury reduces infarct size and promotes functional recovery in neonatal rats.
Tan X; Chen Y; Li J; Li X; Miao Z; Xin N; Zhu J; Ge W; Feng Y; Xu X
Neuroscience; 2015 Apr; 290():552-60. PubMed ID: 25665755
[TBL] [Abstract][Full Text] [Related]
40. Sulforaphene, a CDK5 Inhibitor, attenuates cognitive deficits in a transgenic mouse model of Alzheimer's disease via reducing Aβ Deposition, tau hyperphosphorylation and synaptic dysfunction.
Yang W; Xu QQ; Yuan Q; Xian YF; Lin ZX
Int Immunopharmacol; 2023 Jan; 114():109504. PubMed ID: 36508924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
